Home › Compare › TOKIF vs EQR

TOKIF vs EQR: Dividend Comparison 2026

TOKIF yields 35087.72% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TOKIF wins by $1.4045583093529018e+22M in total portfolio value
10 years
TOKIF
TOKIF
● Live price
35087.72%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.4045583093529018e+22M
Annual income
$13,967,277,210,808,802,000,000,000,000.00
Full TOKIF calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — TOKIF vs EQR

📍 TOKIF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTOKIFEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TOKIF + EQR cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
TOKIF pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TOKIF
Annual income on $10K today (after 15% tax)
$2,982,456.14/yr
After 10yr DRIP, annual income (after tax)
$11,872,185,629,187,480,000,000,000,000.00/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, TOKIF beats the other by $11,872,185,629,187,480,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TOKIF + EQR for your $10,000?

TOKIF: 50%EQR: 50%
100% EQR50/50100% TOKIF
Portfolio after 10yr
$7.022791546764509e+21M
Annual income
$6,983,638,605,404,401,000,000,000,000.00/yr
Blended yield
99.44%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

TOKIF
No analyst data
Altman Z
8.4
Piotroski
4/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TOKIF buys
0
EQR buys
0
No recent congressional trades found for TOKIF or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTOKIFEQR
Forward yield35087.72% ✓5.87%
Annual dividend / share$2.00$3.47 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8% ✓
Portfolio after 10y$1.4045583093529018e+22M$47.8K ✓
Annual income after 10y$13,967,277,210,808,802,000,000,000,000.00 ✓$5,475.61
Total dividends collected$1.4040435209834525e+22M$23.0K ✓
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: TOKIF vs EQR ($10,000, DRIP)

YearTOKIF PortfolioTOKIF Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$3,519,472$3,508,771.93$11,380$679.82+$3.51M → TOKIF
2$1,157,880,257$1,154,114,421.98$13,014$837.25+$1157.87M → TOKIF
3$356,094,180,688$354,855,248,813.21$14,961$1,036.20+$356094.17M → TOKIF
4$102,373,625,569,446$101,992,604,796,109.58$17,297$1,289.22+$102373625.55M → TOKIF
5$27,513,170,932,649,252$27,403,631,153,289,944.00$20,121$1,613.15+$27513170932.63M → TOKIF
6$6,912,425,278,424,497,000$6,882,986,185,526,563,000.00$23,561$2,030.84+$6912425278424.47M → TOKIF
7$1,623,550,972,939,442,000,000$1,616,154,677,891,527,600,000.00$27,783$2,573.54+$1623550972939442.00M → TOKIF
8$356,497,181,763,681,700,000,000$354,759,982,222,636,500,000,000.00$33,013$3,284.39+$356497181763681664.00M → TOKIF
9$73,183,067,962,816,976,000,000,000$72,801,615,978,329,840,000,000,000.00$39,547$4,223.51+$73183067962816978944.00M → TOKIF
10$14,045,583,093,529,017,000,000,000,000$13,967,277,210,808,802,000,000,000,000.00$47,791$5,475.61+$1.4045583093529018e+22M → TOKIF

TOKIF vs EQR: Complete Analysis 2026

TOKIF — Stock

Optima Medical Innovations Corp. produces and sells hemp-based cannabidiol (CBD) products in Canada and internationally. It offers industrial hemp-derived CBD oil, airless metered pens, capsules, topicals, and tinctures. The company also operates multidisciplinary pain clinics, which focuses on the treatment of chronic pain, including comprehensive, medical, and interventional pain management; independent medical evaluations; physiotherapy and chiropractic care; and medical cannabis and platelet rich plasma therapy, as well as mindfulness teaching. It has a research agreement with the Ryerson University for medical cannabis research and new medical grade products development. The company was formerly known as Tree of Knowledge International Corp. and changed its name to Optima Medical Innovations Corp. in November 2021. Optima Medical Innovations Corp. is based in Toronto, Canada.

Full TOKIF Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this TOKIF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TOKIF vs SCHDTOKIF vs JEPITOKIF vs OTOKIF vs KOTOKIF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.